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MaOBJECTIVES This study investigates the inﬂuence of implantation depth and prosthesis oversizing on conduction
abnormalities (CA) and permanent pacemaker implantation (PPI) after SAPIEN 3 (Edwards Lifesciences, Irvine, California)
implantation.
BACKGROUND CA and PPIs are frequent complications after transcatheter aortic valve replacement with a next-
generation balloon-expandable transcatheter heart valve (SAPIEN 3). The potential underlying mechanisms are incom-
pletely understood.
METHODS Of 244 patients treated with SAPIEN 3,208 without a previous pacemaker and 184 without baseline CA were
analyzed. We assessed the association of angiographic implantation depth (% of frame height below the annulus) and
degree of oversizing with PPI and CA.
RESULTS New PPI and new or worsened CA or PPI occurred in 16% (34 of 208) and 31% (57 of 184), respectively.
Patients requiring PPI had a higher prevalence of atrial ﬁbrillation (44% vs. 24%; p ¼ 0.017), complete right bundle
branch block (27% vs. 5%; p ¼ 0.001), and bradycardia (<60 beats/min, 38% vs. 21%; p ¼ 0.034). In patients with new
CA or PPI, implantation depth was lower (at septal side: 29  8% vs. 25  7%; p ¼ 0.003), and rate of oversizing was
higher (19% [11 of 57] vs. 6% [8 of 126]; p ¼ 0.007). Independent predictors of new or worsened CA or PPI were
implantation depth at septal side (odds ratio [OR]: 1.063 [95% conﬁdence interval (CI): 1.017 to 1.110]; p ¼ 0.006 per
% of frame below the aortic annulus), oversizing (OR: 3.489 [95% CI: 1.236 to 9.848]; p ¼ 0.018), and QRS duration
(OR: 1.033 [95% CI: 1.011 to 1.056]; p ¼ 0.003 per ms).
CONCLUSIONS Implantation depth and prosthesis oversizing were associated with a higher rate of new CA or PPI using
the SAPIEN 3. Thus, avoidance of deep implantation and extreme oversizing may reduce these complications.
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245AB BR E V I A T I O N S
AND ACRONYM S
CA = conduction abnormalities
CI = conﬁdence interval
LBBB = left bundle branch
block
OR = odds ratio
PPI = permanent pacemaker
implantation
RBBB = right bundle branch
block
TAVR = transcatheter aortic
valve replacementP ost-procedural new or worsened conductionabnormalities (CA) and permanent pacemakerimplantation (PPI) after transcatheter aortic
valve replacement (TAVR) remain a serious concern.
The incidence of new or worsened CA, in particular
complete left bundle branch block (LBBB) and PPI
with balloon-expandable valves has been reported to
be between 8% and 30% (1–5) and 5% and 12% (6–8),
respectively. Although PPI does not seem to affect
survival (9,10), overall costs and hospital stay are
increased (11) and symptomatic beneﬁt may be
limited (12). New or worsened CA may negatively
affect left ventricular function recovery and increase
the risk for PPI during follow-up (13,14).
Recently, a balloon-expandable prosthesis
(SAPIEN 3, Edwards Lifesciences, Irvine, California)
(15) has been introduced featuring a highermetal frame
with an outer skirt designed to avoid paravalvular
leakage. The clinical experience with this device is
limited, but ﬁrst results are excellent (16). However,
regarding post-procedural PPI, preliminary studies
report a relatively high rate, ranging from 13% to 25.5%
(16–18).SEE PAGE 255The development of new devices should weigh
potential improvements, like minimizing para-
valvular leakage and vascular complications, against
an increase in PPI and CA. Minimizing these com-
plications is mandatory for further improvement in
TAVR outcome, especially in intermediate-risk pa-
tients. Therefore, determinants of PPI and CA need
to be identiﬁed. Possible causes include technical
issues, but also the appropriateness of sizing
algorithms.
We aimed to examine potential determinants of
new PPI and CA with the SAPIEN 3 valve using
clinical, electrocardiographic, angiographic, and CT-
morphological parameters.
METHODS
PATIENT POPULATIONS. We treated 244 consecu-
tive patients with the SAPIEN 3 valve at our institu-
tion. TAVR was performed in a hybrid operation suite
under general anesthesia or conscious sedation using
the transfemoral approach. All patients provided
written informed consent for the procedure.
To determine the incidence of new PPI after TAVR,
patients with previous pacemaker (n ¼ 23, 9%),
atypical valvular anatomy (bicuspid valve; n ¼ 5, 1%)
or degenerated biological prostheses (n ¼ 8, 3%) were
excluded, resulting in 208 patients. Of these patients,
those with complete bundle branch blocks at baselinewere excluded (n ¼ 24) to analyze the inci-
dence of new or worsened CA or PPI after
TAVR, leaving 184 patients (Figure 1).
MULTISLICE COMPUTED TOMOGRAPHY
DATA ANALYSIS. Aortic annulus measure-
ments were assessed in diastole using multi-
ple plane reconstruction according to the
guidelines of the Society of Cardiovascular
Computed Tomography (19). Area and
perimeter of the aortic annulus were obtained
by direct planimetry. An approximation of
the minimal and maximum diameters was
manually obtained (Figure 2) to calculate the
eccentricity of the aortic annulus as the eccentricity
index using the formula: 1  (minimum diameter/
maximum diameter). The closer this index comes to
zero, the more circular the aortic annulus.
Calciﬁcation of the valvular apparatus was
assessed at the height of the aortic cusps, annulus,
and left ventricular outﬂow tract and was visually
graded as none ¼ 0, mild ¼ 1, moderate ¼ 2, and
severe ¼ 3. Dedicated Food and Drug Administration–
approved software (OsiriX MD 3.9.4, Pixmeo,
Switzerland) was used.
PROSTHESIS SIZE SELECTION. The SAPIEN 3 valve is
available in 23-, 26-, and 29-mm sizes. The di-
mensions of a nominal expanded SAPIEN 3 and the
manufacturer’s sizing recommendations are given in
Table 1. The ﬁnal decision on prosthesis size was left
to the discretion of the physicians performing the
procedure and was mainly based on multislice
computed tomography (MSCT)–derived annular area
and taking into account other anatomical features like
presence and distribution of calciﬁcation, eccentricity
of the aortic annulus, and also the patient anatomy
in case of borderline sizing ranges. Percentage of
oversizing according to area and perimeter were
calculated using the formula: (nominal prosthesis
dimension/patient anatomy  1)$100. The adherence
to the manufacturer’s sizing guidelines by annular
area was categorized as “undersized,” “within sizing
range,” and “oversized.”
DETERMINATION OF IMPLANTATION DEPTH. Angio-
graphic data were transferred to a separate worksta-
tion and assessed ofﬂine using Food and Drug
Administration–approved software (OsiriX MD 3.9.4,
Pixmeo, Switzerland). The implantation plane was
identiﬁed using previously described techniques, by
either calculation from the MSCT (20) or by combi-
nation of angiographic and ﬂuoroscopic guidance
(21). A pigtail was placed in the right coronary cusp,
and an orthogonal view on the 3 aortic cusps
was conﬁrmed by aortic angiography. The ﬁnal
FIGURE 1 Patient Flow, Reasons for Exclusion From Analyses, and Incidence of
PPI and New or Worsened CA
CA ¼ conduction abnormalities; LAHB ¼ left anterior hemiblock; LBBB ¼ left bundle
branch block; LPHB ¼ left posterior hemiblock; PPI¼ permanent pacemaker implantations;
RBBB ¼ right bundle branch block.
Husser et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 3 , 2 0 1 6
Predictors of PPI in S3 F E B R U A R Y 8 , 2 0 1 6 : 2 4 4 – 5 4
246post-deployment aortic angiogram was selected
showing the prosthesis in an orthogonal view. The
native aortic annulus was marked by intersecting the
sinuses of Valsalva. The entire prosthesis frame
height and the portion below the aortic annulus were
measured at the septal (i.e., noncoronary cusp) and
nonseptal (i.e., left coronary cusp) sides. Implanta-
tion depth was expressed as the percentage of frame
height below the aortic annulus (Figure 3).
ELECTROCARDIOGRAPHIC ANALYSIS. Electrocardio-
grams (ECGs) were recorded on admission and before
discharge and were reviewed by 2 physicians blinded
to clinical data according to recommendations issued
by the American Heart Association/American College
of Cardiology Foundation/Heart Rhythm Society (22).
Doubtful cases were solved by consensus. Rhythm,
heart rate (beats/min), PQ and QRS intervals (ms),
atrioventricular conduction disturbances, and intra-
ventricular conduction abnormalities were recorded.
Due to potential interference of pacemaker stimula-
tion, intraventricular conduction was not evaluated
in patients who underwent PPI after TAVR and was
instead denoted as “pacemaker.”
DEFINITION OF ENDPOINTS. Endpoints of the study
were PPI before discharge in patients without previ-
ous pacemaker (n ¼ 208) and new or worsened CA
or PPI in patients without bundle branch blocks or
pacemaker at baseline (n ¼ 184) (see Figure 1 and
previous section).The treating physicians made the ﬁnal decision for
PPI, and the indication was recorded in every case.
New or worsened CA was deﬁned as new complete
LBBB or right bundle branch block (RBBB) at
discharge.
All data were prospectively collected. In-hospital
outcome, device success, and procedural com-
plications were categorized according to the Valve
Academic Research Consortium (23).
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD or as the median (inter-
quartile range [IQR]) and were compared using the
unpaired Student t test or Mann-Whitney U test as
appropriate. Discrete variables were compared with
the chi-square test or Fisher exact test as appropriate.
To identify independent predictors for PPI and new or
worsened CA, multivariable logistic regression
models were applied, adjusted by variables yielding a
p < 0.1 in univariate analyses or variables known to
inﬂuence either endpoint. To assess the impact of
oversizing by area and implantation depth, these
variables were included in the models. Odds ratios
(ORs) with the respective 95% conﬁdence intervals
(CIs) were computed. A 2-sided p value <0.05 was
considered to be statistically signiﬁcant. SPSS Statis-
tics version 22 (IBM, Armonk, New York) was used for
analyses.
RESULTS
Clinical baseline, electrocardiographic, and proce-
dural characteristics of the study population are
displayed in Tables 2 and 3. Mean age was 81 years
with a logistic EuroSCORE of 16%. TAVR was per-
formed using the 23-, 26-, and 29-mm SAPIEN 3 valve
in 44%, 38%, and 18% of cases, respectively. Device
success was achieved in 98%, with post-procedural
paravalvular insufﬁciency $2 in 2% of cases.
Conscious sedation was used in 39% of cases. Median
hospital stay was 5 days, and there was no in-hospital
death.
Implantation depth (% of frame height below the
aortic annulus) was evaluated in 207 patients (1 case
was performed under echocardiographic guidance
without contrast administration due to pre-operative
severe renal failure). Mean implantation depth was
26  7% (range 6% to 48%, Table 3).
MSCT data and degree of oversizing are displayed
in Tables 4 and 5 and are available for 206 patients, as
2 patients did not undergo MSCT due to renal failure.
The median percentage of oversizing according to
annular area and perimeter was 7% and 2%, respec-
tively. Prosthesis selection was within range in 77%
(159 of 206), undersized in 12% (24 of 206), and
FIGURE 2 MSCT Analysis and Calculation of Oversizing
Example of multislice computed tomography (MSCT) analysis and calculation of oversizing in a patient with a 26-mm SAPIEN 3 (Edwards Lifesciences, Irvine, California).
Nominal area of a 26-mm SAPIEN 3 (5.19 cm2) was divided by patient anatomy (4.52 cm2) to obtain the degree of area oversizing (14.8%). Note that minimal and
maximal diameters were not automatically obtained but were manually drawn to allow for an approximation of annulus eccentricity. For details, see the Methods section.
ACC ¼ non (a-)coronary cusp; LCC ¼ left coronary cusp; RCC ¼ right coronary cusp.
TABLE 1 SAPIEN 3 Nominal Prosthesis Dimensions and Sizing Recommendations
23 mm 26 mm 29 mm
Frame height, mm 18 20 22.5
Outer diameter, mm 22.75 25.71 28.75
Outer perimeter, mm 71.47 80.74 90.32
Outer area, cm2 4.06 5.19 6.48
Recommended range (area), cm2 3.38–4.30 4.30–5.46 5.40–6.80
Recommended range (area-derived diameter), mm 20.7–23.4 23.4–26.4 26.2–29.4
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247oversized in 11% (23 of 206) of cases. Mean oversizing
by area and implantation depth in these categories
was 7.3  6.6% and 26  8%, 9.3  3.8% and 24  6%,
and 26.7  5.2% and 28  6%, respectively.
NEW PPIS AFTER SAPIEN 3 IMPLANTATION. After
TAVR with the SAPIEN 3, 16% (34 of 208) underwent
PPI before discharge (Figure 1). Indication and timing
for PPI is provided in Online Table 1. Intraventricular
conduction at baseline and discharge is displayed in
Figure 4A. Patients undergoing PPI had a higher
prevalence of atrial ﬁbrillation (44% vs. 24%;
p ¼ 0.017), complete RBBB (27% vs. 5%; p ¼ 0.001),
and bradycardia (<60 beats/min, 38% vs. 21%;
p ¼ 0.034) (Table 2) at baseline.
Depth of implantation and its association with PPI
are displayed in Table 3. Patients with PPI had a trend
toward deeper implantation, especially at the non-
septal side, without statistical signiﬁcance. Post-
dilation was not associated with PPI (32% vs. 35%;
p ¼ 0.762).
In MSCT data, the degree of oversizing and
adherence to sizing recommendations are displayed
in Tables 4 and 5. There was no difference in the
degree of median area oversizing in patients with orwithout PPI after TAVR (6% [IQR: 2% to 11%] vs. 8%
[IQR: 1% to 15%]; p ¼ 0.566) nor was there a difference
in degree of calciﬁcation or eccentricity index be-
tween both groups.
In a multivariable analysis, independent pre-
dictors of PPI were previous RBBB (OR: 11.965 [95%
CI: 3.406 to 42.026]; p < 0.001), atrial ﬁbrillation (OR:
3.996 [95% CI: 1.567 to 10.192]; p ¼ 0.004), heart rate
on admission (OR: 0.941 [95% CI: 0.907 to 0.977];
p ¼ 0.001, per beat/min increase), previous unspe-
ciﬁc intraventricular conduction abnormality (OR:
10.022 [95% CI: 1.644 to 61.083]; p ¼ 0.012), COPD
(OR: 4.660 [95% CI: 1.513 to 14.405]; p ¼ 0.007), and
implantation depth at the nonseptal side (OR: 1.066
FIGURE 3 Determination of Implantation Depth
Example of deep (A) and high (B) implanted SAPIEN 3 (Edwards Lifesciences, Irvine, California). Final post-deployment aortic angiogram shows
the prosthesis in an orthogonal view. The native aortic annulus was marked by intersecting the sinus of Valsalva. The entire prosthesis
frame height (long arrows) and the portion below the aortic annulus (short arrows) were measured at the septal (i.e., noncoronary cusp) and
nonseptal (i.e., left coronary cusp) sides. Implantation depth was expressed as percentage of frame height below the aortic annulus.
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248[95% CI: 1.066 to 1.127]; p ¼ 0.022, per % of frame
below annulus), but not prosthesis oversizing (OR:
0.217 [95% CI: 0.026 to 1.780]; p ¼ 0.155). No differ-
ence in incidence of PPI was observed across the
tertiles of consecutive cases (p for trend 0.327)
(Online Figure 1).
NEW-ONSET OR WORSENED CA OR PPI AFTER
SAPIEN 3 IMPLANTATION. The overall incidence of
new or worsened CA or PPI was 31% (57 of 184)
(Figure 1): PPI in 14% (25 of 184), LBBB in 16% (30 of
184), and RBBB in 1% (2 of 184). Intraventricular
conduction at baseline and at discharge is displayed
in Figure 4B. At baseline, patients with new CA or PPI
had a longer QRS duration (100  24 ms vs. 93  11 ms;
p ¼ 0.006) and a higher prevalence of nonspeciﬁc
intraventricular conduction abnormalities (9% vs. 1%;
p ¼ 0.011; Table 2).Implantation depth was lower in patients with new
or worsened CA or PPI, especially at the septal side
(29  8% of frame height below annulus vs. 25  7%;
p ¼ 0.003). Patients in the upper quartile of mean im-
plantation depth (range 30% to 48% of frame below
annulus) exhibited a signiﬁcantly higher rate of new
or worsened CA or PPI as compared with lower quar-
tiles (46% [21 of 46] vs. 26% [36 of 138]; p ¼ 0.013).
New CA or PPI were more frequent under conscious
sedation (51% vs. 35%; p ¼ 0.037), but there was no
associationwith post-dilation (33% vs. 38%; p¼0.561).
Percentages of oversizing, valvular calciﬁcation, or
annulus eccentricity were not signiﬁcantly different
in patients with new or worsened CA or PPI compared
with those without (Table 4). However, in case of
out-of-range prosthesis oversizing, the rate of new or
worsened CA or PPI was signiﬁcantly higher (58%
[11 of 19] vs. 28% [46 of 164]; p ¼ 0.007).
TABLE 2 Baseline and ECG Characteristics
All Patients
(n ¼ 208)
New Permanent Pacemaker PPI and New or Worsened CA
Yes (n ¼ 34) No (n ¼ 174) p Value Yes (n ¼ 57) No (n ¼ 127) p Value
Clinical characteristics
Age, yrs 81  6 82  6 81  6 0.194 82  6 80  6 0.012
Female 94 (45) 11 (32) 83 (48) 0.100 28 (49) 59 (47) 0.738
Logistic EuroSCORE, % 16  12 19  15 15  12 0.106 17  13 14  10 0.065
NYHA functional class III/IV 135 (65) 28 (79) 108 (62) 0.053 41 (72) 76 (60) 0.115
COPD 27 (13) 8 (24) 19 (11) 0.045 8 (14) 14 (11) 0.560
PAD 28 (14) 4 (12) 24 (14) 0.999 8 (14) 16 (13) 0.789
Extracardiac arteriopathy 58 (28) 9 (27) 49 (28) 0.841 16 (28) 33 (26) 0.767
GFR, ml/min 54  37 49  29 55  39 0.409 49  27 58  43 0.162
Coronary artery disease 137 (66) 23 (68) 114 (66) 0.811 41 (72) 83 (65) 0.379
Myocardial infarction 19 (9) 3 (9) 16 (9) 0.999 5 (9) 13 (10) 0.757
PCI 81 (39) 15 (44) 66 (38) 0.499 22 (39) 52 (41) 0.764
CABG 12 (6) 3 (9) 9 (5) 0.419 4 (7) 6 (5) 0.503
Diabetes mellitus 59 (28) 11 (32) 48 (28) 0.573 14 (25) 35 (28) 0.671
Stroke 20 (10) 1 (3) 19 (11) 0.209 4 (7) 14 (11) 0.398
LVEF <35% 21 (10) 4 (12) 17 (10) 0.756 7 (12) 10 (8) 0.340
Electrocardiographic data
Atrial ﬁbrillation 57 (27) 15 (44) 42 (24) 0.017 15 (26) 31 (24) 0.782
Heart rate, beats/min 72  14 68  15 73  14 0.073 69  13 73  14 0.107
Bradycardia <60 beats/min 50 (24) 13 (38) 37 (21) 0.034 19 (33) 27 (21) 0.080
PQ interval, ms 181  37 197  44 179  35 0.035 182  43 181  34 0.955
AVB I 34 (16) 8 (24) 26 (15) 0.216 12 (21) 19 (15) 0.307
QRS duration, ms 100  22 115  31 98  19 <0.001 100  24 93  11 0.006
LAHB 20 (10) 3 (9) 17 (10) 0.999 5 (9) 15 (12) 0.540
Incomplete RBBB 3 (1) 0 (0) 3 (2) 0.999 1 (2) 2 (2) 0.999
Nonspeciﬁc IVCA 6 (3) 3 (9) 3 (2) 0.057 5 (9) 1 (1) 0.011
RBBB 18 (9) 9 (27) 9 (5) 0.001 — — —
LBBB 6 (3) 0 (0) 6 (3) 0.592 — — —
Values are mean  SD or n (%).
AVBI ¼ ﬁrst degree atrioventricular block with PQ duration >200 ms in patients with sinus rhythm; CA ¼ conduction abnormalities; CABG ¼ coronary artery bypass graft;
COPD ¼ chronic obstructive pulmonary disease; ECG ¼ electrocardiogram; GFR ¼ glomerular ﬁltration rate; IVCA ¼ intraventricular conduction abnormalities; LAHB ¼ left
anterior hemiblock; LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; PAD ¼ peripheral artery disease;
PCI ¼ percutaneous coronary intervention; RBBB ¼ right bundle branch block.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 3 , 2 0 1 6 Husser et al.
F E B R U A R Y 8 , 2 0 1 6 : 2 4 4 – 5 4 Predictors of PPI in S3
249The independent predictors for new or worsened
CA or PPI were implantation depth at the septal side
(OR: 1.063 [95% CI: 1.017 to 1.110]; p ¼ 0.006 per each
% of frame below the aortic annulus), out-of-range
prosthesis oversizing (OR: 3.489 [95% CI: 1.236 to
9.848]; p ¼ 0.018), and QRS duration on admission
(OR: 1.033 [95% CI: 1.011 to 1.056]; p ¼ 0.003 per ms).
However, there was no difference in incidence of new
or worsened CA or PPI across the tertiles of consecu-
tive cases (p for the trend ¼ 0.962) (Online Figure 1).DISCUSSION
In the present study, we report the rate of PPI and
new or worsened CA with the SAPIEN 3 device.
Although yielding excellent clinical results in terms
of device success and in-hospital mortality, we found
a relatively high rate of PPI and new or worsenedCA. In a comprehensive analysis, we identiﬁed a
strong inﬂuence of implantation depth and extreme
prosthesis oversizing on the occurrence of new or
worsened CA.
PPIS AND NEW OR WORSENED CA AFTER
TAVR—INCIDENCE AND CLINICAL EFFECT. The
incidence of PPI after TAVR with balloon-expandable
valves, especially with the Edwards SAPIEN XT,
ranges between 5% to 12% (6–8), and the effect on
clinical outcome remains controversial. Although no
negative effect on survival has been observed (9,10),
PPI may limit clinical beneﬁt from TAVR due to lack
of AV-synchrony and right ventricular pacing (12).
Additionally, PPI after TAVR has been identiﬁed as an
important cause of prolonged hospital stay, thereby
increasing procedural costs (11).
There are still limited available data on the inci-
dence of PPI after TAVR with the SAPIEN 3 valve,
TABLE 3 Procedural Characteristics and Outcome
All Patients
(N ¼ 208)
New Permanent Pacemaker PPI and New or Worsened CA
Yes (n ¼ 34) No (n ¼ 174) p Value Yes (n ¼ 57) No (n ¼ 127) p Value
Device dimension 0.173 0.576
23 mm 91 (44) 12 (35) 79 (45) 24 (42) 60 (47)
26 mm 79 (38) 12 (35) 67 (39) 21 (37) 48 (38)
29 mm 38 (18) 10 (29) 28 (16) 12 (21) 19 (15)
Conscious sedation 81 (39) 17 (50) 64 (37) 0.148 29 (51) 44 (35) 0.037
Procedural time, min 61  24 61  21 61  24 0.929 61  27 61  23 0.967
Fluoroscopy time, min 16  16 13  5 16  17 0.353 13  4 16  15 0.186
Contrast, ml 116  67 92  27 120  71 0.027 109  63 123  71 0.205
Post-dilation 72 (35) 11 (32) 61 (35) 0.762 19 (33) 48 (38) 0.561
Multiple valves 1 (1) 0 (0) 1 (1) 0.999 0 (0) 1 (1) 0.999
Paravalvular leakage IIþ 4 (2) 1 (3) 3 (2) 0.513 1 (2) 3 (2) 0.999
Device success 203 (98) 33 (97) 170 (98) 0.999 56 (98) 123 (97) 0.999
Days in hospital 6  4 7  3 6  4 0.118 7  3 6  4 0.313
Intrahospital death 0 (0) 0 (0) 0 (0) — 0 (0) 0 (0) —
30-day mortality 1 (0.5) 1 (3) 0 (0) 0.163 0 (0) 0 (0) —
Depth of implantation, % of frame height below aortic annulus at:
Septal side, NCC 26  8 27  9 26  8 0.265 29  8 25  7 0.003
Nonseptal side, LCC 26  7 28  9 25  7 0.081 27  8 25  7 0.035
Mean 26  7 28  9 25  7 0.145 28  8 25  7 0.010
Values are n (%) or mean  SD.
CA ¼ conduction abnormalities; LCC ¼ left coronary cusp; NCC ¼ noncoronary cusp; PPI ¼ permanent pacemaker implantation.
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250although emerging ﬁgures indicate a rate of PPI
between 13% and 25.5% (16–18). In a preliminary se-
ries analyzing the SAPIEN 3 prosthesis, our group
found a PPI rate of 12.5% (24). With increasing expe-
rience, this rate was not reduced and was 16% in this
extended patient cohort, which is in line with the
mentioned reports from the published data.
There are other reasons for an elevated PPI rate
apart from device- or technical-related causes.
One reason may be a substantial percentage ofTABLE 4 MSCT Measurements of the Aortic Annulus
All Patients
(N ¼ 206)
New Permanen
Yes (n ¼ 34) No
Minimal diameter, mm 21.03  2.35 21.61  2.33 20.9
Maximal diameter, mm 26.94  2.70 27.78  2.90 26.7
Eccentricity index 0.22  0.06 0.22  0.07 0.2
Perimeter, mm 77.06  7.43 79.10  7.51 76.6
% oversizing 2 [1 to 5] 1 [0 to 3] 2 [
Area, cm2 4.62  0.91 4.87  0.91 4.5
% oversizing 7 [0 to 14] 6 [2 to 11] 8 [
Degree of calciﬁcation
Cusps, moderate/severe 148 (72) 24 (71) 12
Annulus, moderate/severe 21 (10) 3 (9) 1
LVOT, moderate/severe 12 (6) 2 (6) 1
Values are mean  SD or n (%) or median [interquartile range].
LVOT ¼ left ventricular outﬂow tract; MSCT ¼ multislice computed tomography; othepre-existent RBBB. As reported in previous studies
(25) and in a recent meta-analysis (8), pre-existing
RBBB is a strong predictor for PPI after TAVR. This
was also observed in our study, where baseline ECG
parameters were most important for the prediction of
PPI.
The incidence of new or worsened CA after TAVR
with balloon-expandable valves ranges between
8% and 30% (1–5). Although no effect on mortality
could be demonstrated (2), new or worsened CA aret Pacemaker PPI and New or Worsened CA
(n ¼ 172) p Value Yes (n ¼ 57) No (n ¼ 126) p Value
1  2.34 0.116 20.98  2.52 20.99  2.25 0.983
7  2.64 0.046 26.89  2.69 26.84  2.68 0.906
2  0.06 0.799 0.22  0.06 0.22  0.06 0.727
6  7.37 0.080 76.97  7.68 76.85  7.34 0.920
2 to 5] 0.495 2 [0 to 6] 2 [2 to 5] 0.209
7  0.91 0.083 4.61  0.95 4.60  0.90 0.932
1 to 15] 0.566 6 [2 to 15] 7 [1 to 19] 0.177
4 (72) 0.859 30 (68) 93 (74) 0.452
8 (11) 0.999 9 (16) 12 (10) 0.218
0 (6) 0.999 5 (9) 7 (6) 0.521
r abbreviations as in Table 3.
TABLE 5 Prosthesis Sizing According to Sizing Recommendation by MSCT-Derived Area
All Patients
(N ¼ 206)
New Permanent Pacemaker PPI and New or Worsened CA
Yes (n ¼ 34) No (n ¼ 172) p Value Yes (n ¼ 57) No (n ¼ 126) p Value
Undersized 24 (12) 2 (6) 22 (13) 0.097 3 (5) 20 (16) 0.007
Within sizing range 159 (77) 31 (91) 128 (74) 43 (75) 98 (78)
Oversized 23 (11) 1 (3) 22 (13) 11 (19) 8 (6)
23-mm SAPIEN 3 prosthesis 91 (44) 12 (35) 79 (46) — 24 (42) 60 (48) —
Undersized 13 (14) 1 (8) 12 (15) 0.269 1 (4) 11 (18) 0.166
Within sizing range 67 (74) 11 (92) 56 (71) 19 (79) 44 (73)
Oversized 11 (12) 0 (0) 11 (14) 4 (17) 5 (8)
26-mm SAPIEN 3 prosthesis 77 (37) 12 (35) 65 (38) — 21 (37) 48 (38) —
Undersized, 8 (10) 1 (8) 7 (11) 0.404 2 (10) 6 (13) 0.049
Within sizing range 61 (79) 11 (92) 50 (78) 14 (67) 39 (83)
Oversized 8 (10) 0 (0) 8 (12) 5 (24) 2 (4)
29-mm SAPIEN 3 prosthesis 38 (18) 10 (29) 28 (16) — 12 (21) 19 (15) —
Undersized 3 (8) 0 (0) 3 (11) 0.551 0 (0) 3 (16) 0.235
Within sizing range 31 (82) 9 (90) 22 (79) 10 (83) 15 (79)
Oversized 4 (11) 1 (10) 3 (11) 2 (17) 1 (5)
Values are n (%).
MSCT ¼ multislice computed tomography; other abbreviations as in Table 3.
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251associated with impaired recovery of left ventricular
function (13,14). Also, a higher risk of late PPI due to
new or worsened CA (4,5) may prompt prophylactic
PPI in these patients.
Data on the incidence of new or worsened CA after
TAVR with the SAPIEN 3 as well as the potential
determinants are scarce. Recent data from 150 pa-
tients treated with this device indicated an incidence
of LBBB of 21%; however, the underlying mechanisms
were not addressed (16). In the present study, we
found new LBBB in 16% of patients not undergoing
TAVR-related PPI and a strong relationship to im-
plantation depth and prosthesis oversizing. Previous
studies have shown that new-onset CA after TAVR
with balloon-expandable valves may be dynamic, and
a certain percentage resolves after implantation to
hospital discharge and during follow-up (2). In the
present study, we have focused on the pre-discharge
ECG. The degree of resolution of new-onset CA with
the SAPIEN 3 during follow-up still needs to be
investigated.
ROLE OF IMPLANTATION DEPTH AND PROSTHESIS
OVERSIZING. A deeper positioning of the prosthesis
below the aortic annulus might cause CA via me-
chanical stress and direct damage of the conduction
system. Accordingly, depth of implantation has been
identiﬁed as a predictor of new or worsened CA,
mainly with self-expandable but also balloon-
expandable valves (2,26,27). The present study ex-
tends these ﬁndings to the SAPIEN 3 valve, showing
depth of implantation as an independent predictor ofnew or worsened CA or PPI. The SAPIEN 3 valve
possesses a higher frame and extends deep into the
left ventricular outﬂow tract (15). However, in case of
PPI, results were not univocal. Recently, in a very
small sample size of 29 patients, Tarantini et al. (17)
found a relation between implantation depth and
PPI (17), whereas the present study found only a trend
toward deeper implantations in case of PPI.
The role of MSCT-guided prosthesis sizing and
oversizing has been investigated primarily to
address paravalvular leakage (28). Recently, Yang
et al. (29) have demonstrated that the SAPIEN 3 valve
requires less annular oversizing to prevent para-
valvular leakage. However, data on the inﬂuence of
MSCT-derived measures of oversizing with PPI and
new or worsened CA are scarce, as this issue has
mainly been addressed using echocardiography
(30,31). We found a strong relationship of out-of-
range oversizing with the incidence of new CA or
PPI. Indeed, extreme out-of-range oversizing resul-
ted in a 3- to 4-fold increase in new or worsened CA
or PPI. Of note, the sizing range assessed in this study
includes the recommended sealing zones for pros-
theses deployed with nominal volumes and not the
areas in which prosthesis size may still be considered
adequate when underﬁlled. The observation that
oversizing was associated with new or worsened CA
but not with PPI has been observed before using post-
procedural MSCT data (32). For prevention of para-
valvular leakage, a modest degree of oversizing of the
SAPIEN 3 valve seems sufﬁcient (29), whereas
excessive oversizing increases the risk of new CA and
FIGURE 4 Intraventricular Conduction at Baseline and Before Discharge
Intraventricular conduction at baseline and before discharge in the population for PPI analysis (A) and for new or worsened CA or PPI (B).
Abbreviations as in Figure 1.
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252PPI. This should be considered in future sizing
recommendations.
A somewhat counterintuitive ﬁnding in this study
is the weak relationship between PPI and both over-
sizing and depth of implantation. PPI after TAVR is a
more multifactorial phenomenon than the rather
objective ECG endpoint “new or worsened CA.” Thereare several clinical scenarios, unrelated to the pro-
cedure itself, that may lead to PPI after TAVR,
including a pre-existing indication for pacing (e.g.,
pre-existent sick sinus syndrome and pauses) or a
prophylactic indication (e.g., tri-fascicular block or
bradycardia). Therefore, PPI may be a somewhat
subjective endpoint to analyze, and the effect of
PERSPECTIVES
WHAT IS KNOWN? Post-procedural new or worsened CA and
PPI after TAVR with the SAPIEN 3 remain of concern, and their
incidence and predictors are unclear.
WHAT IS NEW? Using the SAPIEN 3 in 208 patients, the inci-
dence of new PPI and new or worsened CA or PPI was 16.4% and
31%, respectively. Implantation depth and extreme prosthesis
oversizing were predictors of new CA or PPI using the SAPIEN 3.
WHAT IS NEXT? Future studies should assess if higher
implantation and avoidance of extreme oversizing lead to a
decrease in PPI and new or worsened CA using the SAPIEN 3
device.
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253implantation depth and oversizing may thus become
more difﬁcult to evaluate. Moreover, it is possible
that in the absence of pre-existent CA, direct trauma
to the left bundle branch during deployment of the
prosthesis may cause new CA but not necessarily
complete heart block requiring PPI. However, given
that patients with new onset of CA had a 2-fold
elevated rate of PPI compared with patients without
CA (30% [14 of 46] vs. 12% [20 of 162]; p ¼ 0.003), and
the fact that other studies have also been able to
demonstrate a direct relationship of implantation
depth with PPI after TAVR with the SAPIEN 3 (17),
there is a clear suggestion of the importance of both
appropriate valve sizing and implantation depth to
achieve better outcomes.
STUDY LIMITATIONS. Using ﬂuoroscopic images of-
fers an approximation of implantation depth, which
in certain cases may be subject to underestimation
due to discrepancies between the annulus plane and
prosthesis plane.
CONCLUSIONS
In a large population of patients undergoing TAVR
with the SAPIEN 3 valve, we found an overall inci-
dence of new or worsened CA or PPI in 1 of 3 patients
and a clear relationship to implantation depth andout-of-range extreme oversizing. An adjustment of
implantation height and careful adherence to the
sizing algorithms may result in a reduction of new or
worsened CA or PPI.
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